# A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive

> **NCT03812809** · PHASE2 · COMPLETED · sponsor: **Beta Pharma Shanghai** · enrollment: 226 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** BPI-7711

## Key facts

- **NCT ID:** NCT03812809
- **Lead sponsor:** Beta Pharma Shanghai
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-05
- **Primary completion:** 2022-01-24
- **Final completion:** 2022-01-24
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2022-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03812809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03812809, "A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03812809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*